Taipei [July 27, 2022] – Mycenax Biotech (TWO: 4726), a pioneer in Taiwan for biopharmaceutical CDMO services, announced today that the board of directors has finalized plans for private placement.
This private placement focused on a few key investors, of which JCR Pharmaceuticals Co., Ltd., a distinguished Japanese biopharmaceutical company, has become the largest shareholder (20.48%), followed by CENTER Laboratories, Inc. (20.46%).
In this private placement, JCR Pharmaceuticals Co., Ltd. purchased 42,000,000 shares and CENTER Laboratories, Inc. purchased 8,000,000 shares with a price at 32.5 NTD per share. The private placement was expected to reach a total amount of 1,625,000,000 NTD (~54.3 million USD).
About JCR Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. JCR improves patients’ lives by applying scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR’s approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia, with investigational products in development worldwide aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level.
In the fiscal year of 2021 (2021/4/1~2022/3/31), JCR annual revenue reached 51,082 million yen (about 372.9 million USD), and the net profit reached 20% (19,933 million yen, about 4.5E billion NTD), This was an increase of 69.8% and 141.1% respectively over the previous year.
Company website: https://www.jcrpharm.co.jp/en/site/en/
About Mycenax
Founded in September 2001, Mycenax Biotech is a fully integrated CDMO company based in Taiwan focused on providing a full range of services for biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 1.55 billion NTD (51.8 million USD) and an estimated capital of 2.05 billion NTD (~68.4 million USD) following private placement.
Stock code: Mycenax Biomedical (4726).
Company website: http://www.mycenax.com.tw
Future Outlook
Over the past few years, Mycenax has further expanded on its capability of complete integration of upstream and downstream processes coupled to cGMP production at the international stage, with 80% of its revenue from foreign markets (e.g. Japan, South Korea, Singapore). JCR, a longtime customer of Mycenax, has established a smooth cooperation model with Mycenax for the optimization of biopharmaceutical process development and GMP production operation, which lends to the common standards and direction that both companies strive towards. JCR’s central basis of “Quality over Quantity” and their corporate value of “contributing to human health through drugs” resonate equally with Mycenax, capturing the belief both companies have in providing high-quality refined services and medicines. These shared values establish synergistic cooperation in this partnership for win-win situations as the private equity investment from JCR affirms Mycenax’s professional technology and services, doubling as a boost to Mycenax’s long term development. Mycenax hopes to continually build on the synergy established with JCR, improving operational efficiency and strengthening international competitiveness, to accelerate Mycenax’s vision of becoming a base for global biopharmaceutical development and production.
Press Contact:
Stacy Sun
Email: stacy.sun@mycenax.com.tw
Taipei [July 27, 2022] – Mycenax Biotech (TWO: 4726), a pioneer in Taiwan for biopharmaceutical CDMO services, announced today that the board of directors has finalized plans for private placement.
This private placement focused on a few key investors, of which JCR Pharmaceuticals Co., Ltd., a distinguished Japanese biopharmaceutical company, has become the largest shareholder (20.48%), followed by CENTER Laboratories, Inc. (20.46%).
In this private placement, JCR Pharmaceuticals Co., Ltd. purchased 42,000,000 shares and CENTER Laboratories, Inc. purchased 8,000,000 shares with a price at 32.5 NTD per share. The private placement was expected to reach a total amount of 1,625,000,000 NTD (~54.3 million USD).
About JCR Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. JCR improves patients’ lives by applying scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. JCR’s approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia, with investigational products in development worldwide aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level.
In the fiscal year of 2021 (2021/4/1~2022/3/31), JCR annual revenue reached 51,082 million yen (about 372.9 million USD), and the net profit reached 20% (19,933 million yen, about 4.5E billion NTD), This was an increase of 69.8% and 141.1% respectively over the previous year.
Company website: https://www.jcrpharm.co.jp/en/site/en/
About Mycenax
Founded in September 2001, Mycenax Biotech is a fully integrated CDMO company based in Taiwan focused on providing a full range of services for biological drugs. At its core, Mycenax is committed to the development and production of biological drugs, from the R&D phase to cGMP manufacturing plants to drug commercialization. Mycenax, as an international CDMO company, continuously invests in product development innovations and technology platform optimizations in order to provide customers with comprehensive and streamlined CDMO services. Mycenax Biotech currently has a capital of 1.55 billion NTD (51.8 million USD) and an estimated capital of 2.05 billion NTD (~68.4 million USD) following private placement.
Stock code: Mycenax Biomedical (4726).
Company website: http://www.mycenax.com.tw
Future Outlook
Over the past few years, Mycenax has further expanded on its capability of complete integration of upstream and downstream processes coupled to cGMP production at the international stage, with 80% of its revenue from foreign markets (e.g. Japan, South Korea, Singapore). JCR, a longtime customer of Mycenax, has established a smooth cooperation model with Mycenax for the optimization of biopharmaceutical process development and GMP production operation, which lends to the common standards and direction that both companies strive towards. JCR’s central basis of “Quality over Quantity” and their corporate value of “contributing to human health through drugs” resonate equally with Mycenax, capturing the belief both companies have in providing high-quality refined services and medicines. These shared values establish synergistic cooperation in this partnership for win-win situations as the private equity investment from JCR affirms Mycenax’s professional technology and services, doubling as a boost to Mycenax’s long term development. Mycenax hopes to continually build on the synergy established with JCR, improving operational efficiency and strengthening international competitiveness, to accelerate Mycenax’s vision of becoming a base for global biopharmaceutical development and production.
Press Contact:
Stacy Sun
Email: stacy.sun@mycenax.com.tw